The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of alisertib as a single agent in recurrent or progressive atypical teratoid rhabdoid tumors.
 
Santhosh Upadhyaya
Research Funding - Novartis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Olivia Campagne
No Relationships to Disclose
 
Giles W. Robinson
Consulting or Advisory Role - Lilly; Roche/Genentech
Research Funding - Genentech/Roche (Inst); Novartis (Inst); Novartis (Inst)
 
Arzu Onar-Thomas
Honoraria - Lilly
Research Funding - Apexigen (Inst); Celgene (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Lilly
 
Brent Orr
No Relationships to Disclose
 
Catherine A Billups
No Relationships to Disclose
 
Ruth G Tatevossian
No Relationships to Disclose
 
Alberto Broniscer
Consulting or Advisory Role - Tocagen
 
Lindsay Baker Kilburn
Employment - Kaiser Permanente (I)
Consulting or Advisory Role - Roche/Genentech
Research Funding - Epizyme (Inst); Novartis (Inst)
 
Patricia Ann Baxter
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Novartis (Inst); PTC Therapeutics (Inst)
 
Amy A. Smith
No Relationships to Disclose
 
John Crawford
No Relationships to Disclose
 
Sonia Partap
No Relationships to Disclose
 
David W. Ellison
No Relationships to Disclose
 
Clinton F. Stewart
No Relationships to Disclose
 
Zoltan Patay
No Relationships to Disclose
 
Amar J. Gajjar
Research Funding - Genentech (Inst); Kazia Therapeutics (Inst)